Scholars Central

OtherPublished 23 Jul 2016

Advances in targeted therapy for melanoma: a focus on MEK inhibition

Authors: April KS Salama, Kevin B Kim

Clinical Investigation

Volume 4 · Issue 10 · Pages 903–913

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Increased knowledge of the role that dysregulated MAPK signaling plays in melanoma has opened the door for novel therapeutic strategies, among them MEK-targeted approaches. With the recent approval of the selective MEK inhibitor trametinib, both as a single agent and in combination with dabrafenib for patients with BRAF-mutant metastatic melanoma, MEK-based therapy now has a place as a standard of care option for the treatment of this disease. Early data suggest a benefit of MEK inhibition in other melanoma subtypes as well, including NRAS-mutant and uveal melanoma. This review summarizes the clinical development and the currently available data regarding the role of MEK inhibitor therapy in the treatment of advanced melanoma.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “April KS Salama”
  • BylineArticles whose byline prints “Kevin B Kim”